Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 29, 2020
Daily News
June 29, 2020
- Toshio Nakagawa Elected as New Chief of Japan Medical Association
June 29, 2020
- 418 Key Drug Candidates Listed by 36 Societies, Panel to Outline Stable Supply Measures at Next Meeting
June 29, 2020
- PMDA Reviewing Safety Risk for 10 Contrast Agents
June 29, 2020
- Mitsubishi Tanabe Files Inebilizumab in Japan for NMOSD
June 29, 2020
- Pfizer Japan Boosting Biosimilar Sales Structure with Dedicated Unit, Ups Its Quality Pitch
June 29, 2020
- AstraZeneca in Talks with Daiichi Sankyo, Meiji Group on COVID-19 Vaccine Supplies in Japan
June 29, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…